If you suffered losses in AlloVir stock, contact AlloVir stock loss lawyer Timothy L. Miles about an AlloVir lawsuit
INTRODUCTION TO THE ALLOVIR CLASS ACTION LAWSUIT
The AlloVir class action lawsuit seeks to represent purchasers or acquirers of AlloVir, Inc. (NASDAQ: ALVR) securities between March 22, 2022 and December 21, 2023, inclusive (the “Class Period”). Captioned Zerbato v. AlloVir, Inc., No. 24-cv-10152 (D. Mass.), the AlloVir class action lawsuit charges AlloVir and certain of AlloVir’s top executives with violations of the Securities Exchange Act of 1934.
If you suffered losses in AlloVir stock and wish to serve as lead plaintiff in the AlloVir class action lawsuit, or just have general questions about your rights as a shareholder, please contact AlloVir Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the AlloVir class action lawsuit must be filed with the court no later than March 19, 2024. Read on to learn the answers to the six most frequently asked questions about the AlloVir class action lawsuit. what are the ALLEGATIONS IN THE ALLOVIR CLASS ACTION LAWSUIT?
AlloVir is a clinical-stage cell therapy company that engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat viral-associated diseases. According to the complaint, in March 2022, AlloVir initiated global phase 3 registrational studies of its lead product posoleucel for the prevention of life-threatening viral infections from viruses in high-risk, allogeneic hematopoietic cell transplant patients (the “posoleucel Phase 3 Studies”).
The AlloVir class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that AlloVir would ultimately discontinue the posoleucel Phase 3 Studies; and (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel. The AlloVir class action lawsuit further alleges that on December 22, 2023, AlloVir announced that it was discontinuing the posoleucel Phase 3 Studies after pre-planned analyses concluded they would not meet their primary endpoints and stated that it would explore strategic alternatives for AlloVir. On this news, the price of AlloVir stock fell more than 67%, according to the complaint. WHAT IS THE LEAD PLAINTIFF DEADLINE IN THE ALLOVIR CLASS ACTION LAWSUIT?
When a securities class action is filed such as the AlloVir class action lawsuit, the person who files the first complaint is required to publish a notice announcing the filing. Anyone who wants to be lead plaintiff on behalf of the class in the AlloVir class action lawsuit must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.
WHAT DO THE PLAINTIFFS HAVE TO PROVE TO PREVAIL IN THE ALLOVIR CLASS ACTION LAWSUIT?
To understand the basis of the AlloVir class action lawsuit, it is essential to grasp the key elements of securities fraud actions. The majority of securities fraud claims are brought under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. To prevail in a Rule 10b-5 action, a plaintiff must establish six elements:
WHAT IS THE LEAD PLAINTIFF PROCESS IN THE ALLOVIR CLASS ACTION LAWSUIT?
The PSLRA permits any investor who purchased and suffered losses in AlloVir stock to seek appointment as lead plaintiff in the AlloVir class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.
A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit. An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in AlloVir stock and have further questions, contact AlloVir stock loss Lawyer Timothy L. Miles today who would fight to recover your damages in an AlloVir class action lawsuit if you suffered losses in AlloVir stock. CAN A NON-U.S. INVESTOR SERVE AS LEAD PLAINTIFF IN THE ALLOVIR CLASS ACTION LAWSUIT?
Yes, courts in the U.S. have consistently recognized that non-U.S. investors, many of whom have substantial holdings, are adequate lead plaintiffs and have the same right to move for lead plaintiffs as U.S. investors. Thus, if a non-U.S. investor suffered losses in AlloVir stock, they may move the Court to be appointed lead plaintiff in the AlloVir class action lawsuit.
WILL THE LEAD PLAINTIFFS GET MORE MONEY THAN CLASS MEMBERS IF THE ALLOVIR CLASS ACTION LAWSUIT SETTLES?
No, but they may be entitled to recover their reasonable expenses incurred with are directly related to representing the class in the AlloVir class action lawsuit. Under the PSLAR, a Lead Plaintiff is only entitled to his or her pro rata share of any recovery and does not receive any additional money for serving as a representative party on behalf of the class. However, a court, in its discretion, may approve an award of “reasonable costs and expenses (including lost wages)” to a Lead Plaintiff that directly relates to the representation of the class in the AlloVir class action lawsuit on behalf of investors who suffered losses in AlloVir stock.
CONTACT AN ALLOVIR STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN ALLOVIR STOCK ABOUT AN ALLOVIR CLASS ACTION LAWSUIT
If you suffered losses in AlloVir stock, contact AlloVir stock loss lawyer Timothy L. Miles today for a free case evaluation about an AlloVir class action lawsuit. Call today and see what an AlloVir stock loss lawyer could do for you if you suffered losses in AlloVir stock.
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846–6529 Email: [email protected] AlloVir stock loss lawyer Timothy L. MilesNashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association,Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America’s Most Honored Lawyers 2020 – Top 1% by America’s Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime. Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
October 2024
Categories
All
|
CONTACT
The Law Offices of Timothy L. Miles Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846-6529 Email: [email protected] HOURS OF OPERATION Mon-Fri: 24/7 Sat-Sun: 24/7 |
SECURITIES FRAUD
GitLab, Inc. Acadia Healthcare Sunlight Financial Iris Energy Limited Edwards Lifesciences Elanco Animal Health, Inc. MASS TORTS
Takata Airbag Settlement |